Similar articles

• A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

  Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ; Valganciclovir Study Group. Martin DF, et al. N Engl J Med. 2002 Apr 11;346(15):1119-26. doi: 10.1056/NEJMoa011759. N Engl J Med. 2002. PMID: 11948271 Clinical Trial.
• Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.

  Freeman RB. Freeman RB. Expert Opin Pharmacother. 2004 Sep;5(9):2007-16. doi: 10.1517/14656566.5.9.2007. Expert Opin Pharmacother. 2004. PMID: 15330737 Review.
• Cytomegalovirus retinitis: new developments in prophylaxis and therapy.

  Jacobson MA. Jacobson MA. AIDS Clin Rev. 1997-1998:249-69. AIDS Clin Rev. 1997. PMID: 9305451 Review. No abstract available.
• CMV retinitis trial expanding.

  Vazquez E. Vazquez E. Posit Aware. 1998 Jan-Feb;9(1):16. Posit Aware. 1998. PMID: 11364995
• New drugs for treating CMV. Valcyte, an oral compound, expands the treatment options for people with CMV retinitis.

  Eagan L. Eagan L. Posit Living. 2001 Oct-Nov;10(6):13. Posit Living. 2001. PMID: 11702748 No abstract available.